Stay updated on Johnson & Johnson Press Releases
Sign up to get notified when there's something new on the Johnson & Johnson Press Releases page.
Latest updates to the Johnson & Johnson Press Releases page
- Check6 days agoChange DetectedNew press releases dated Oct 31–Oct 24, 2025 were added to the listing, expanding the current feed. Deletions remove older results and items as part of content curation.SummaryDifference8%
- Check13 days agoChange DetectedNew press releases and highlights have been added, including Nipocalimab, icotrokinra, and Impella updates. Older items such as the Orthopaedics separation announcement and detailed Q3 2025 financial results were removed.SummaryDifference8%
- Check20 days agoChange DetectedMajor additions introduce new clinical results, regulatory milestones, and strategic corporate actions; deletions remove some neuropsychiatry portfolio notes and lower-impact press items.SummaryDifference100%
- Check28 days agoChange DetectedExpanded clinical/regulatory spotlight with many new approvals, trial results, and conference appearances; removed an older foundation investment note and several earlier items.SummaryDifference100%
- Check35 days agoChange DetectedDifference24%
- Check42 days agoChange DetectedSummary: The page now adds new items on seltorexant’s potential benefit in depression with insomnia and a $5M expansion by the J&J Foundation for community health workers, while removing recent NSCLC trial news about rybrevant lazertinib. The focus shifts toward mood disorder pharmacology and health workforce investment at the expense of oncology first-line therapy news.SummaryDifference34%
Stay in the know with updates to Johnson & Johnson Press Releases
Enter your email address, and we'll notify you when there's something new on the Johnson & Johnson Press Releases page.